Vaccinate before the next pandemic?

Nature

Volumn 465, Issue 7295, 2010, Pages 161-

  Stöhr, Klaus ^a,b  

^a Department of Novartis Vaccines and Diagnostics ^*  (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; INFLUENZA VACCINE; VACCINE;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG UTILIZATION; EPIDEMIC; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A H1N1; MEXICO; NOTE; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH; VACCINATION; VIRUS; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TIME FACTORS; VACCINATION; WORLD HEALTH;

EID: 77952327363     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/465161a     Document Type: Note

References (4)

1. Chan, M. World Now at the Start of 2009 Influenza Pandemic (WHO, 2009); available at go.nature.com/5tufc3
2. Fidler, D. P. PLoS Med. 7, e1000247 (2010).
3. Stephenson, I. et al. N. Engl. J. Med. 359, 1631-1633 (2008).
4. European Medicines Agency Fourteenth Pandemic Pharmacovigilance Update (EMA, 2010); available at go.nature.com/GnDjSD